1374 related articles for article (PubMed ID: 8616953)
41. Serum levels of IgM, IgD, IgA and IgG before and during rejection of renal allotransplants.
Hrncír Z; Erben J; Tichý M
Czech Med; 1979; 2(3):148-56. PubMed ID: 394945
[TBL] [Abstract][Full Text] [Related]
42. Results of the conversion to everolimus in renal transplant recipients with posttransplantation malignancies.
Chiurchiu C; Carreño CA; Schiavelli R; Petrone H; Balaguer C; Trimarchi H; Pujol GS; Novoa P; Acosta F; González C; Arriola M; Massari PU;
Transplant Proc; 2010; 42(1):277-9. PubMed ID: 20172329
[TBL] [Abstract][Full Text] [Related]
43. Study on the role of humoral immunity in renal transplant rejections and its correlation with histopathological findings.
Sonkar GK; ; Singh RG
Saudi J Kidney Dis Transpl; 2011 Sep; 22(5):901-10. PubMed ID: 21912017
[TBL] [Abstract][Full Text] [Related]
44. In vitro donor-specific hyporesponsiveness and T cell subsets in renal allograft recipients.
Bas J; Mestre M; Griñó JM; Massip E; Castelao AM; Romeu A; González L; Valls A; Buendía E
Allergol Immunopathol (Madr); 1993; 21(4):136-40. PubMed ID: 8237717
[TBL] [Abstract][Full Text] [Related]
45. Comparison of Minnesota antilymphoblast globulin and Upjohn antithymocyte globulin for induction immunosuppression of human renal allografts.
Pescovitz MD; Book BK; Milgrom ML; Leapman SB; Petersen B; Filo RS
Surgery; 1994 Oct; 116(4):811-8. PubMed ID: 7940183
[TBL] [Abstract][Full Text] [Related]
46. Prognostic value of T lymphocyte subset ratios for renal transplant survival in patients on different immunosuppressive regimens.
Henny FC; van Es A; Oljans PJ; Baldwin WM; Tanke HJ; van Es LA; Paul LC
Clin Exp Immunol; 1986 Aug; 65(2):373-80. PubMed ID: 3024886
[TBL] [Abstract][Full Text] [Related]
47. Extended experience with a steroid minimization immunosuppression protocol in pediatric renal transplant recipients.
Lau KK; Berg GM; Schjoneman YG; Perez RV; Butani L
Pediatr Transplant; 2010 Jun; 14(4):488-95. PubMed ID: 19849807
[TBL] [Abstract][Full Text] [Related]
48. Intracellular ATP levels in CD4+ lymphocytes are a risk marker of rejection and infection in renal graft recipients.
Pérez-Flores I; Sánchez-Fructuoso A; Santiago JL; Fernández-Arquero M; Calvo N; de la Concha EG; Barrientos A
Transplant Proc; 2009; 41(6):2106-8. PubMed ID: 19715845
[TBL] [Abstract][Full Text] [Related]
49. Serum IgG subclasses in chronic and recurrent respiratory infections.
Stanley PJ; Corbo G; Cole PJ
Clin Exp Immunol; 1984 Dec; 58(3):703-8. PubMed ID: 6509800
[TBL] [Abstract][Full Text] [Related]
50. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients.
Puissant-Lubrano B; Rostaing L; Kamar N; Abbal M; Fort M; Blancher A
Exp Clin Transplant; 2010 Mar; 8(1):19-28. PubMed ID: 20199367
[TBL] [Abstract][Full Text] [Related]
51. Esophageal candidiasis after renal transplantation: comparative study in patients on different immunosuppressive protocols.
Gupta KL; Ghosh AK; Kochhar R; Jha V; Chakrabarti A; Sakhuja V
Am J Gastroenterol; 1994 Jul; 89(7):1062-5. PubMed ID: 8017366
[TBL] [Abstract][Full Text] [Related]
52. Reversal of cardiac transplant rejection without massive immunosuppression.
Michler RE; Smith CR; Drusin RE; Reison DS; Hickey TJ; Lamb J; Reemtsma K; Rose EA
Circulation; 1986 Nov; 74(5 Pt 2):III68-71. PubMed ID: 3533317
[TBL] [Abstract][Full Text] [Related]
53. Immunosuppression by Cyclosporin A in human renal transplant recipients.
Ringdén O; Bergstrand A; Collste H; Grimfors G; Lundgren G; Groth CG
Scand J Urol Nephrol Suppl; 1981; 64():220-9. PubMed ID: 6755683
[TBL] [Abstract][Full Text] [Related]
54. [Plasmapheresis in the combined treatment of the kidney transplant rejection crisis].
Serniak PS; Kovalenko NV; Bogomolov AM; Zakharov VV; Chernobrivtsev PA
Urol Nefrol (Mosk); 1989; (4):7-10. PubMed ID: 2800082
[TBL] [Abstract][Full Text] [Related]
55. Immune monitoring with a lymphocyte adenosine triphosphate assay in kidney transplant recipients treated with a calcineurin inhibitor.
Sugiyama K; Tsukaguchi M; Toyama A; Satoh H; Saito K; Nakagawa Y; Takahashi K; Tanaka S; Onda K; Hirano T
Exp Clin Transplant; 2014 Jun; 12(3):195-9. PubMed ID: 24907718
[TBL] [Abstract][Full Text] [Related]
56. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients.
Mariat C; Alamartine E; Diab N; de Filippis JP; Laurent B; Berthoux F
Transpl Int; 1998; 11(3):231-6. PubMed ID: 9638854
[TBL] [Abstract][Full Text] [Related]
57. IgG subclasses in monoclonal gammopathy of undetermined significance.
Kyle RA; Gleich GJ
J Lab Clin Med; 1982 Nov; 100(5):806-14. PubMed ID: 7130836
[TBL] [Abstract][Full Text] [Related]
58. Antithymocyte globulin in cadaver renal grafts: prophylaxis and antirejection therapy with three different preparations.
MacDonald AS; Belitsky P; Lannon SG; Cohen A; White J
Transplant Proc; 1982 Dec; 14(4):631-4. PubMed ID: 6762719
[TBL] [Abstract][Full Text] [Related]
59. Lower homocysteine levels in renal transplant recipients treated with everolimus: a possible link with a decreased cardiovascular risk?
Farsetti S; Zanazzi M; Caroti L; Rosso G; Larti A; Marcucci R; Fedi S; Rogolino A; Cellai AP; Abbate R; Bertoni E; Salvadori M
Transplant Proc; 2010 May; 42(4):1381-2. PubMed ID: 20534308
[TBL] [Abstract][Full Text] [Related]
60. Infectious complications associated with renal transplantation: an analysis of risk factors.
Ahern MJ; Comite H; Andriole VT
Yale J Biol Med; 1978; 51(5):513-25. PubMed ID: 373266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
